Molecular-genetic diagnostics of von Hippel-Lindau syndrome (VHL) in Bulgaria: first complex mutation event in the VHL gene

Int J Neurosci. 2018 Feb;128(2):117-124. doi: 10.1080/00207454.2017.1372436. Epub 2017 Sep 13.

Abstract

Von Hippel-Lindau syndrome is an autosomal-dominant disease characterized by the formation of various tumours and cysts in many different parts of the body. Von Hippel-Lindau syndrome is caused by VHL gene mutations leading to production of impaired tumor suppressor Von Hippel-Lindau syndrome protein or its complete absence.

Purpose: To study five patients with clinically suspected Von Hippel-Lindau syndrome, who were referred for molecular genetic testing.

Methods: Sanger sequencing of the coding regions of the VHL gene.

Results: Five clinically relevant germline mutations were detected. One of the pathogenic variants has not been previously reported. This novel mutation is a complex mutation event combining a duplication and an indel, rearranging exon 3 of the VHL gene - c. [516_517dupGTCAAGCCT; 532_542delCTGGACATCGTinsATTA], p. (Glu173Serfs*4).

Conclusion: Overall, our results showed that the diagnosis of Von Hippel-Lindau syndrome in our country is difficult most probably because of its heterogeneous clinical manifestation and insufficient knowledge on the diagnostic criteria for the disease. From genetic point of view our results add some novel data on the mutation profile of the VHL gene. In order to prove or revise the diagnosis, early genetic testing is strongly recommended in affected patients and their family members to ensure appropriate follow-up and treatment of the malignancies.

Keywords: VHL; VHL gene; complex mutation event; haemangioblastoma.

MeSH terms

  • Adolescent
  • Adult
  • Bulgaria
  • DNA Mutational Analysis
  • Female
  • Genetic Testing
  • Humans
  • Middle Aged
  • Molecular Biology
  • Mutation
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics*
  • von Hippel-Lindau Disease / diagnosis*
  • von Hippel-Lindau Disease / genetics

Substances

  • Von Hippel-Lindau Tumor Suppressor Protein
  • VHL protein, human